The Mystery

BPC-157 (Body Protection Compound, a pentadecapeptide from gastric juice) accelerates healing of tendons, ligaments, muscles, and even brain injuries across dozens of rodent studies. Yet despite 100+ papers, no one has nailed down the primary mechanism. The literature is a grab-bag: VEGF, NO, FAK, EGF, FGF — everything goes up. This isn't a mechanism. It's a mystery.

The Hypothesis

BPC-157's tissue-healing effects converge on a single axis: VEGF upregulation → eNOS activation → NO-dependent collagen I/III synthesis in tenocytes. The other growth factor changes are downstream consequences of restored vascularity, not primary drivers.

Mechanism

1. BPC-157 binds an as-yet-unidentified receptor (likely related to the VEGFR2/NRP1 complex) on endothelial cells
2. This activates VEGF transcription via HIF-1α stabilization — even under normoxic conditions
3. VEGF drives angiogenesis at the injury site, restoring blood supply
4. Increased blood flow delivers oxygen → eNOS generates NO
5. NO directly stimulates tenocyte collagen synthesis via cGMP/PKG pathway
6. The cascade: BPC-157 → VEGF → angiogenesis → eNOS/NO → collagen deposition → healed tendon

Evidence Basis

• Sikiric et al. (multiple papers): BPC-157 effects are abolished by L-NAME (NOS inhibitor) and rescued by L-arginine
• Chang et al. (2011): BPC-157 increases VEGF expression 4-fold in rat tendon fibroblasts
• Tendon injuries in BPC-157-treated rats show increased CD34+ vessel density at injury sites
• NO donors alone accelerate tendon healing (albeit less than BPC-157)

Proposed Test

1. Rat Achilles tendon transection model, 4 groups:
   • Vehicle
   • BPC-157 (10 μg/kg IP daily)
   • BPC-157 + bevacizumab (VEGF-neutralizing antibody)
   • BPC-157 + L-NAME (NOS inhibitor)
2. Endpoints at 2 and 4 weeks: biomechanical strength (load-to-failure), collagen I/III ratio (Masson's trichrome), vessel density (CD31 IHC), NO metabolites (nitrite/nitrate in tissue)
3. Prediction: Both bevacizumab and L-NAME will abolish >80% of BPC-157's healing effect, confirming the VEGF-NO axis is necessary and sufficient

Implications

If this axis is confirmed, it opens rational drug design around BPC-157's mechanism. Instead of injecting a peptide with unclear pharmacokinetics, we could develop small-molecule VEGF-NO axis activators with proper oral bioavailability and defined PK. It also validates the biohacker community's intuition — BPC-157 works — while giving it a mechanistic home. The body already knows how to heal. Sometimes it just needs a reminder.